Digest Network Come funziona
Digest / Comunicato

RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME

Compatibilità
Salva(0)
Condividi
RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME
Materiali Allegati (1)

216_153452_2025_oneinfo.pdf

Scarica Press Kit ->
Recapiti

Comunicati correlati

16/04/2025
Biotecnologia
Pubblicità/Marketing/Media/Comunicazione
Annunci Economici
RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME
Fonte
RECORDATI
Emittente
GLOBENEWSWIRE
Scopri affinità
0
Press Release cover image
11/11/2025
Biotecnologia
Pubblicità/Marketing/Media/Comunicazione
Annunci Economici
RECORDATI FIRST NINE MONTHS 2025 RESULTS: REVENUE +12.2%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +10.7%; ISTURISA PEAK SALES ESTIMATE DOUBLED TO GREATER THAN € 1.2 BILLION
Fonte
RECORDATI
Emittente
GLOBENEWSWIRE
Scopri affinità
0
11/11/2025
Finanza
Risparmio/Affari personali
Fondi di investimento
Industria
RECORDATI FIRST NINE MONTHS 2025 RESULTS: REVENUE +12.2%, EBITDA +11.8%, ADJUSTED NET INCOME +10.7%; ISTURISA PEAK SALES ESTIMATE DOUBLED TO GREATER THAN € 1.2 BILLION
Fonte
RECORDATI
Emittente
1INFO
Scopri affinità
0